

April 05, 2019

The Manager, Listing Department The National Stock Exchange of India Ltd. Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai - 400 051 NSE Symbol: PANACEABIO

BSE Limited Corporate Relationship Department, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001 BSE Scrip Code: 531349

Sub: Corrigendum-2 to the Notice of Extraordinary General Meeting of the Company

Dear Sir/Madam,

In continuation to the Notice dated February 26, 2019 for the Extraordinary General Meeting ("EGM Notice"), of the members of Panacea Biotec Limited, held on Monday, March 25, 2019 at 11:30 A.M. at Ambala-Chandigarh Highway, Lalru-140501, Punjab, read with the Corrigendum dated March 20, 2019 published on March 21, 2019 in respect of special resolution to create, offer, issue and allot, in one or more tranches upto 71,11,111 (Seventy One Lakhs Eleven Thousand One Hundred Eleven) convertible warrants ("Warrants") of Rs.180/- (Rupees One Hundred Eighty) each ("Warrant Issue Price"), exercisable into equal number of equity shares of face value of Re.1/- each for cash at a price of Rs.180/- including premium of Rs.179/- per equity share, on a preferential basis to entities/ persons as mentioned in the explanatory statement to the EGM Notice. The said special resolution has been passed by the Members with requisite majority.

In this regard Members are hereby informed that the details regarding ultimate beneficial ownership of the proposed Allottees of Warrants in terms of SEBI Circular No. CIR/MIRSD/2/2013 dated January 24, 2013 on "Guidelines on identification of beneficial ownership", are as under:

1. India Resurgence Fund - Scheme 1 is a Scheme launched by India Resurgence Fund, a SEBI registered Category II Alternative Investment Fund and do not have any natural person(s) holding more than 15% of the beneficial interest in them. They also do not have any Key Managing Personnel. They are managed by India Resurgence Asset Management Business Private Limited ("Fund Manager").

The Key Management of the said Fund Manager is as under:

1.	Mr. Shantanu Nalavadi	Managing Director
----	-----------------------	-------------------

2. India Resurgence Fund - Scheme 2 is a Scheme launched by India Resurgence Fund, a SEBI registered Category II Alternative Investment Fund and do not have any natural person(s) holding more than 15% of the beneficial interest in them. They also do not have any Key Managing Personnel. They are managed by India Resurgence Asset Management Business Private Limited ("Fund Manager").



Cont....2

B1 Extn. /G3, Mohan Co-op Indl. Estate. Mathura Road, New Delhi -110044 Email: vinodgoel@panaceabiotec.com Phone: D.I.D. +91-11-4167 9015 Fax: +91-11-4167 9070

Panacea Biotec Ltd.

The Key Management of the said Fund Manager is as under:

1.	Mr. Shantanu Nalavadi	Managing Director
----	-----------------------	-------------------

3. **Piramal Enterprises Ltd.** is an entity listed on NSE & BSE. Hence, no further detail of natural persons who are the ultimate beneficial owners is required to be given.

On and from the date hereof, the EGM Notice as amended by Corrigendum dated March 20, 2019, shall always be read in conjunction with this corrigendum ("Corrigendum-2"). All other contents of the EGM Notice as amended by Corrigendum dated March 20, 2019, save and except as amended/modified by this Corrigendum-2, shall remain unchanged.

The Company shall also give notice of the Corrigendum-2 to the shareholders through newspaper publication and updation on website of the Company at www.panacea-biotec.com. The inconvenience is sincerely regretted.

This is for your kind information and record please.

Thanking you,

Sincerely yours,

For Panacea Biotec Ltd.

Vinod Goel

Group CFO and Head Legal

& Company Secretary